Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ervogastat in Hepatic Impairment
NCT04091061Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ervogastat in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration up to 72 hours, Area Under the Curve From Time 0 to Last Quantifiable Concentration up to 72 hours and 1 more. Started Oct 2019; status: completed.
02
Drugs
ervogastat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04091061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091061.